BIOMAT Database Logo BIOMAT Database Logo

Pertussis-specific cell-mediated immunity in infants after vaccination with a tricomponent acellular pertussis vaccine. 1996

F Zepp, and M Knuf, and P Habermehl, and J H Schmitt, and C Rebsch, and P Schmidtke, and R Clemens, and M Slaoui
Pediatric Immunology and Infectious Diseases, Children's Hospital, Johannes Gutenberg University of Mainz, Germany. zepp@mzdmza.zdv.uni-mainz.de

The aim of this study was to investigate pertussis-specific cell-mediated immunity in infants vaccinated with a tricomponent acellular vaccine. Infants were investigated during a primary vaccination schedule from the third month of life to the sixth month as well as before and after a booster at 15 to 24 months. This is the first report of specific cell-mediated immune responses to pertussis-related antigens in infants below the age of 12 months. Our data show that the vaccine induces T-cell responses specific for the vaccine components, detoxified pertussis toxin, filamentous hemagglutinin, and pertactin, that increase progressively over the course of the vaccination schedule. In contrast to declining antibody titers, cell-mediated immune responses are stable over the postprimary to prebooster period. Vaccination results in a progressive increase in the number of T cells that express activation marker CD45RO preferentially on CD4-positive T cells after stimulation with pertussis antigens. Measurements of cytokine secretion profiles demonstrated a preferential induction of interleukin 2- and gamma interferon-producing T-helper 1 cells and only low production of interleukin 10. The observed persistence of the specific cell-mediated immunity may have a bearing on the protective mechanisms induced by pertussis vaccination. Cell-mediated immunity requires further study, particularly to improve our understanding of the persistence of protection afforded by vaccination up to the administration of booster doses.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D010566 Virulence Factors, Bordetella A set of BACTERIAL ADHESINS and TOXINS, BIOLOGICAL produced by BORDETELLA organisms that determine the pathogenesis of BORDETELLA INFECTIONS, such as WHOOPING COUGH. They include filamentous hemagglutinin; FIMBRIAE PROTEINS; pertactin; PERTUSSIS TOXIN; ADENYLATE CYCLASE TOXIN; dermonecrotic toxin; tracheal cytotoxin; Bordetella LIPOPOLYSACCHARIDES; and tracheal colonization factor. Bordetella Virulence Factors,Agglutinogen 2, Bordetella Pertussis,Bordetella Virulence Determinant,LFP-Hemagglutinin,LP-HA,Leukocytosis-Promoting Factor Hemagglutinin,Lymphocytosis-Promoting Factor-Hemagglutinin,Pertussis Agglutinins,Agglutinins, Pertussis,Determinant, Bordetella Virulence,Factor Hemagglutinin, Leukocytosis-Promoting,Factor-Hemagglutinin, Lymphocytosis-Promoting,Factors, Bordetella Virulence,Hemagglutinin, Leukocytosis-Promoting Factor,LFP Hemagglutinin,LP HA,Leukocytosis Promoting Factor Hemagglutinin,Lymphocytosis Promoting Factor Hemagglutinin,Virulence Determinant, Bordetella
D001886 Bordetella pertussis A species of gram-negative, aerobic bacteria that is the causative agent of WHOOPING COUGH. Its cells are minute coccobacilli that are surrounded by a slime sheath. Bacterium tussis-convulsivae,Haemophilus pertussis,Hemophilus pertussis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000907 Antibodies, Bacterial Immunoglobulins produced in a response to BACTERIAL ANTIGENS. Bacterial Antibodies
D000942 Antigens, Bacterial Substances elaborated by bacteria that have antigenic activity. Bacterial Antigen,Bacterial Antigens,Antigen, Bacterial
D013601 T-Lymphocytes Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen. T Cell,T Lymphocyte,T-Cells,Thymus-Dependent Lymphocytes,Cell, T,Cells, T,Lymphocyte, T,Lymphocyte, Thymus-Dependent,Lymphocytes, T,Lymphocytes, Thymus-Dependent,T Cells,T Lymphocytes,T-Cell,T-Lymphocyte,Thymus Dependent Lymphocytes,Thymus-Dependent Lymphocyte
D014611 Vaccination Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis. Immunization, Active,Active Immunization,Active Immunizations,Immunizations, Active,Vaccinations
D016130 Immunophenotyping Process of classifying cells of the immune system based on structural and functional differences. The process is commonly used to analyze and sort T-lymphocytes into subsets based on CD antigens by the technique of flow cytometry. Lymphocyte Immunophenotyping,Lymphocyte Subtyping,Immunologic Subtyping,Immunologic Subtypings,Lymphocyte Phenotyping,Subtyping, Immunologic,Subtypings, Immunologic,Immunophenotyping, Lymphocyte,Immunophenotypings,Immunophenotypings, Lymphocyte,Lymphocyte Immunophenotypings,Lymphocyte Phenotypings,Lymphocyte Subtypings,Phenotyping, Lymphocyte,Phenotypings, Lymphocyte,Subtyping, Lymphocyte,Subtypings, Lymphocyte

Related Publications

F Zepp, and M Knuf, and P Habermehl, and J H Schmitt, and C Rebsch, and P Schmidtke, and R Clemens, and M Slaoui
Long-term pertussis-specific immunity after primary vaccination with a combined diphtheria, tetanus, tricomponent acellular pertussis, and hepatitis B vaccine in comparison with that after natural infection.
July 2001, Infection and immunity,
F Zepp, and M Knuf, and P Habermehl, and J H Schmitt, and C Rebsch, and P Schmidtke, and R Clemens, and M Slaoui
Pertussis-specific cell-mediated and humoral immunity in adolescents 3 years after booster immunization with acellular pertussis vaccine.
July 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
F Zepp, and M Knuf, and P Habermehl, and J H Schmitt, and C Rebsch, and P Schmidtke, and R Clemens, and M Slaoui
Clinical experience of a tricomponent acellular pertussis vaccine combined with diphtheria and tetanus toxoids for primary vaccination in 22,505 infants.
November 1996, The Journal of pediatrics,
F Zepp, and M Knuf, and P Habermehl, and J H Schmitt, and C Rebsch, and P Schmidtke, and R Clemens, and M Slaoui
Acellular vaccines induce cell-mediated immunity to Bordetella pertussis antigens in infants undergoing primary vaccination against pertussis.
January 1997, Developments in biological standardization,
F Zepp, and M Knuf, and P Habermehl, and J H Schmitt, and C Rebsch, and P Schmidtke, and R Clemens, and M Slaoui
Long-term pertussis-specific immune responses to a combined diphtheria, tetanus, tricomponent acellular pertussis and hepatitis B vaccine in pre-term infants.
July 2002, Vaccine,
F Zepp, and M Knuf, and P Habermehl, and J H Schmitt, and C Rebsch, and P Schmidtke, and R Clemens, and M Slaoui
Antibody and cell-mediated immunity to pertussis 4 years after monovalent acellular pertussis vaccine at birth.
May 2014, The Pediatric infectious disease journal,
F Zepp, and M Knuf, and P Habermehl, and J H Schmitt, and C Rebsch, and P Schmidtke, and R Clemens, and M Slaoui
Pertussis specific cell-mediated immune responses ten years after acellular pertussis booster vaccination in young adults.
January 2016, Vaccine,
F Zepp, and M Knuf, and P Habermehl, and J H Schmitt, and C Rebsch, and P Schmidtke, and R Clemens, and M Slaoui
Primary vaccination of infants with a combined diphtheria-tetanus-acellular pertussis-hepatitis B vaccine.
November 1995, The Pediatric infectious disease journal,
F Zepp, and M Knuf, and P Habermehl, and J H Schmitt, and C Rebsch, and P Schmidtke, and R Clemens, and M Slaoui
Acellular pertussis vaccine hailed for infants.
August 1995, JAMA,
F Zepp, and M Knuf, and P Habermehl, and J H Schmitt, and C Rebsch, and P Schmidtke, and R Clemens, and M Slaoui
Cellular immune responses of preterm infants after vaccination with whole-cell or acellular pertussis vaccines.
February 2010, Clinical and vaccine immunology : CVI,
Copied contents to your clipboard!